As targeting glutamine metabolism is the subject of intensive research due to its potential clinical applications (14), we propose that SNAT2 should be investigated as a predictive biomarker and a potential target for well-defined molecular subtypes (luminal B) of ER+ breast cancer patients and as a combination approach to overcome endocrine therapy resistance. The gene discussed is SLC38A2; the disease is breast carcinoma.